[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-surface-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-surface-disease":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,40,70,97,120,145,169,211,231,255,285,307,332,351,374],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100638948","establishment-of-a-multimodal-standard-database-for-inflammation-related-ophthalmopathy-100638948",false,"NCT07628946","Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy","Inclusion Criteria:\n\n1. Retinal vascular and metabolic-related diseases: Diabetic Retinopathy (DR, including NPDR and PDR), Retinal Vein Occlusion (RVO), Hypertensive Retinopathy.\n2. Degenerative diseases: Age-related Macular Degeneration (including dry and wet forms), Pathologic Myopia (PM), Polypoidal Choroidal Vasculopathy (PCV).\n3. Immune-mediated and inflammatory eye diseases: Uveitis (including primary and secondary), Optic Neuritis, Mooren's Ulcer, and corneal melting associated with systemic immune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).\n4. Anterior segment and ocular surface syndromes: Various types of Dry Eye Disease (DED), Keratoconus, Glaucoma (especially cases with chronic inflammation or long-term medication use).\n5. Developmental fundus diseases in children and adolescents: Coats' Disease, Familial Exudative Vitreoretinopathy (FEVR), Retinopathy of Prematurity (ROP).\n6. Patients with a confirmed diagnosis of fundus diseases, including Diabetic Retinopathy, Pathologic Myopia, Age-related Macular Degeneration, Coats' Disease, Familial Exudative Vitreoretinopathy (FEVR), Retinopathy of Prematurity (ROP), and other adult or pediatric fundus diseases.\n7. Ability to cooperate with study examinations, including acceptance of Ultra-Widefield (UWF) fundus photography, OCT\u002FOCTA, AOSLO, corneal confocal microscopy, meibomian gland function assessment, corneal esthesiometry, and tear film function tests. Image quality must meet analytical standards.\n8. Availability of complete or follow-up accessible ophthalmic medical records.\n9. Blood pressure ≤ 160\u002F100 mmHg (to avoid exacerbating ischemia due to uncontrolled hypertension).\n\nExclusion Criteria:\n\n1. Recent (within the past 3 months) corneal\u002Fconjunctival acute inflammation, ocular surgery, or ocular trauma; or presence of corneal alterations (e.g., contact lens wear).\n2. Fundus images that are uninterpretable or severely obscured (e.g., vitreous hemorrhage).\n3. Use of medications affecting tear secretion (e.g., antihistamines, antidepressants) within the past 30 days.","ALL","3 Years",{"count":18,"type":19},3000,"ESTIMATED","OBSERVATIONAL","Through a systematic observational study, the intrinsic connections and patterns between the occurrence and development of common blinding retinal diseases such as diabetic retinopathy, pathological myopia, and age-related macular degeneration and the changes in fine parameters of the anterior structure of the eye are deeply explored. To achieve this goal, investigators will adopt cutting-edge multimodal imaging technology to simultaneously collect precise data from ocular surface and fundus of participants. By integrating and analyzing these multi-dimensional information from different parts of the same eye, investigators will build a high-quality and standardized ocular surface-fundus associated image database. This database not only aims to reveal potential ocular surface biomarkers that can be used for early warning or auxiliary diagnosis, but also lays a solid data foundation for the future development of artificial intelligence-assisted diagnostic tools and the establishment of a brand-new ocular surface-fundus integrated diagnosis and treatment assessment model.",[23,24,25,26],"Ocular Surface Disease","Inflammatory Disease","Retinal Disease","Choroid Diseases","RECRUITING","2026-06-01",{"date":30,"type":31},"2026-06-05","ACTUAL",{"date":33,"type":31},"2025-11-26",{"date":35,"type":19},"2030-02",{"name":37,"class":38},"Dan Chen","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":39},"100639590","the-effect-of-rinsing-on-ocular-inflammation-and-symptoms-in-patients-with-dry-eye-disease-100639590","NCT07618364","The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease","RINSE-A","Inclusion Criteria:\n\n* MMP-9 Positivity in both eyes\n\nExclusion Criteria:\n\n* Active ocular infection, including bacterial, viral, or fungal conjunctivitis Acute allergic conjunctivitis or severe seasonal ocular allergy flare History of autoimmune ocular surface disease (e.g., Sjögren syndrome, ocular cicatricial pemphigoid, Stevens-Johnson syndrome) Current use of topical anti-inflammatory medications, including corticosteroids, cyclosporine, lifitegrast, or topical NSAIDs within 14-30 days prior to enrollment Initiation of new ocular or systemic anti-inflammatory therapy during the study period Contact lens wear within 12-24 hours prior to testing Ocular surgery or laser procedures within the previous 3-6 months Current punctal plug use or punctal occlusion procedures within the prior 3 months Severe aqueous-deficient dry eye preventing adequate tear sample acquisition or reliable InflammaDry testing Use of preserved artificial tears within a specified washout period Eyelid abnormalities or active blepharitis requiring treatment Pregnancy or breastfeeding (optional depending on IRB requirements) History of hypersensitivity to saline irrigation or study materials Any systemic inflammatory disease judged by investigators to confound tear film MMP-9 level",true,"18 Years",{"count":50,"type":19},33,"INTERVENTIONAL",[53],"NA","The central hypothesis is that inflammation contributes to dry eye and that rinsing the palpebral conjunctiva, bulbar conjunctiva, and fornices will reduce the inflammatory burden on the ocular surface.",[56,57,23],"Dry Eye Syndromes","Dry Eye",[59,60],"ophthalmology","optometry","2026-05-26",{"date":28,"type":31},{"date":64,"type":31},"2022-01-01",{"date":66,"type":19},"2027-12-01",{"name":68,"class":69},"Rinsada","INDUSTRY",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":51,"phases":79,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":39},"100634264","the-efficacy-of-intradermal-acupuncture-for-ocular-surface-diseases-after-intractable-facial-paralysis-100634264","NCT07537426","The Efficacy of Intradermal Acupuncture for Ocular Surface Diseases After Intractable Facial Paralysis","Inclusion Criteria:\n\n* 1.Male or female patients aged 18-65 years.\n* 2.Meets diagnostic criteria for intractable peripheral facial paralysis, with disease duration from 1 month to 1 year. FNGS 2.0 ≥15 points; ENoG shows the ratio of CMAP amplitude≤ 20%.\n* 3.At least one subjective ocular symptom (dryness, foreign body sensation, burning, fatigue, redness, fluctuating vision) and OSDI scores between 30 and 80.\n* 4.Voluntarily provides written informed consent and can comply with treatment and follow-up.\n\nExclusion Criteria:\n\n* 1.Other ocular diseases (glaucoma, keratitis, retinopathy, acute inflammation of conjunctiva, sclera, cornea).\n* 2\\. Intraocular surgery or laser therapy within the past 90 days.\n* 3.Use of systemic or topical antibiotics or tear-affecting drugs within 3 weeks; dry eye medications within 2 weeks.\n* 4.Lacrimal passage obstruction, dacryocystitis, punctal occlusion, or neurological impairment preventing full eyelid closure.\n* 5.Coagulation disorders, open wounds, or local infection at intervention sites.\n* 6.Allergy to press-needle materials (stainless steel, adhesive tape).\n* 7.Pregnancy or lactation.\n* 8.Severe cardiac, hepatic, renal, psychiatric disorders, or malignant tumors.\n* 9.Participation in another clinical trial within the past month.","65 Years",{"count":78,"type":19},78,[53],"The purpose of this study is to explore the clinical efficacy of intradermal acupuncture in the treatment of ocular surface diseases after Intractable Facial Paralysis, and to seek effective and convenient treatment for ocular surface diseases after intractable peripheral facial paralysis. The main question it aims to answer is ： Will the intradermal acupuncture intervention effectively reduce the OSDI score ? The researchers compared the intradermal acupuncture with the placebo-needle to observe whether the intradermal acupuncture could better improve the symptoms.",[82,83,23],"Facial Paralysis, Peripheral","Bell's Palsy",[85,86,87],"sequelae of facial paralysis","ocular surface disease","intradermal acupuncture","2026-04-12",{"date":90,"type":31},"2026-04-17",{"date":92,"type":31},"2026-04-01",{"date":94,"type":19},"2028-03-25",{"name":96,"class":38},"The First Affiliated Hospital of Zhejiang Chinese Medical University",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":51,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":39},"100631568","phase-4-effect-of-acoltremon-ophthalmic-solution-0003-on-signs-and-symptoms-of-ocular-surface-disease-in-stage-i-neurotrophic-keratopathy-patients-with-tear-deficiency-100631568","NCT07502378","Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency","Inclusion Criteria:\n\n* Neurotrophic Keratopathy stage 1 diagnosis based on the following: Presence of 3+ fluorescein staining in central cornea and decreased corneal sensation (Cochet-Bonnet less than 4cm in the central cornea)\n* Baseline unanesthetized Schirmer's test ≤ 10 mm\n* Females of childbearing potential must have a negative pregnancy test.\n* Best corrected distance visual acuity (BCDVA), using corrective lenses, if necessary, in the study eye of at least +1.0 Log MAR (Snellen \\\u003C20\u002F200).\n\nExclusion Criteria:\n\n* Evidence of any active ocular infection or any intraocular inflammation.\n* Evidence of any persistent epithelial defect\u002Fulcer or any corneal scar\u002Fcorneal edema.\n* Presence of any other ocular conditions that require topical medications during the treatment phase.\n* History of severe systemic allergies or severe ocular allergies.\n* Inability to suspend topical medications 8 days prior to the starting date and artificial tears 2 hours prior to the first study visit and remain off for the duration of the study.\n* History of any ocular surgery within three months before study visit 1.\n* Ocular surgery expected during the duration of the study.\n* Use of refractive\u002Ftherapeutic contact lenses during the study period.\n* Female subjects who are pregnant\u002Fhave a positive pregnancy test result or are breastfeeding or intend to become pregnant during the study treatment period.\n* Drug addiction\u002Falcohol abuse.\n* Participation in another clinical trial concurrently",{"count":104,"type":19},50,[106],"PHASE4","STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.",[23,109],"Neurotrophic Keratopathy Stage 1",[23],"2026-03-25",{"date":113,"type":31},"2026-03-31",{"date":115,"type":19},"2026-03-27",{"date":117,"type":19},"2027-08-31",{"name":119,"class":38},"University of South Florida",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":47,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":51,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":39},"100630658","phase-4-this-is-a-single-center-open-label-prospective-study-to-evaluate-the-effect-of-xiidra-lifitegrast-ophthalmic-solution-50-on-tear-film-biomarkers-in-dry-eye-100630658","NCT07490535","This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye","Single-Center, Open-Label Trial to Evaluate the Effect of Lifitegrast Ophthalmic Solution 5.0% on Tear Film Biomarkers in Dry Eye Disease","Inclusion Criteria: DED Subjects receiving Xiidra®\n\n1. At least 18 years of age or older at time of screening\n2. Ability to understand and provide informed consent\n3. Subject reported 6-month history of DED in both eyes\n4. No use of ophthalmic drops other than lifitegrast within 2 hours of tear fluid collection to minimize interference with baseline biomarker levels\n5. Willingness to comply with follow-up schedule and required visits\n6. Corneal fluorescein staining score of inferior 1\u002F3rd of cornea ≥ 2\n7. EDS ≥40 (0-100-point VAS, both eyes) at Day 0\n8. Schirmer ≥ 5 and ≤ 10 (without anesthesia)\n9. Best corrected visual acuity (BCVA) of 0.7 logMAR of better (logMAR \\\u003C0.7; Snellen equivalent score\n\nExclusion Criteria: DED Subjects receiving Xiidra®\n\n1. Have a known hypersensitivity or contraindication to the product or their components.\n2. Active ocular infection within the last 30 days.\n3. Any ocular surgical procedure within the last 6 months.\n4. Any subject who has previously tried and failed a course of lifitegrast.\n5. Unwilling to discontinue contact lens use for the duration of the study.\n6. Any female of childbearing potential (FOCBP) who is unwilling to agree to: a) Have a urine pregnancy testing performed at Baseline (Day 0) b) Use at least 1 medically acceptable form of birth control for at least 14 days prior to the first dose of study drug, throughout the study duration, and for 1 month after the last dose of investigational drug. NOTE: FOCBP include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) NOTE: Acceptable forms of birth control include:\n\n   * Mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom)\n   * Hormonal contraceptive (oral, injectable, implantable, or transdermal)\n   * Intrauterine device, or\n   * Surgical sterilization of male partner at least 3 months prior to the first dose of investigational drug NOTE: For non-sexually active female subjects, abstinence may be regarded as an adequate method of birth control when this is in line with the preferred and usual lifestyle of the subject; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial.\n7. Any male who is unwilling to agree to use at least 1 medically acceptable form of birth control with female partner (FOCBP) who also is not using an acceptable form of birth control (as described above). NOTE: Acceptable forms of birth control include: • True abstinence (when this is in line with the preferred and usual lifestyle of the subject), or • Vasectomy at least 3 months prior to the first dose of study drug. Without a vasectomy, must use condoms with spermicidal foam, gel, film, cream, suppository at least 14 days prior to the first dose of investigational drug and throughout the study duration, and for 1 month after the last dose of the investigational drug.\n8. Pregnancy or lactation\n9. Current or past treatment with prescription drops for dry eye within the last six weeks.\n10. Any ocular condition that, in the opinion of the investigator, could affect study parameters including, but not limited to, lid margin disorders (e.g. Blepharitis, staphylococcal, demodex etc.)\n11. Any known history of immunodeficiency disorder, human immunodeficiency virus, hepatitis B or C, evidence of acute active hepatitis A (antihepatitis A virus immunoglobulin M), or organ or bone marrow transplant.\n12. Any known history of alcohol and\u002For drug abuse within 12 months prior to the screening visit that, in the opinion of the investigator, may have interfered with study compliance, outcome measures, safety parameters, and\u002For the general medical condition of the subject.\n\nInclusion Criteria: (Non-DED) subjects not receiving Xiidra® (non-treatment arm)\n\n1. At least 18 years of age or older at time of screening\n2. Ability to understand and provide informed consent\n3. No use of ophthalmic drops within 2 hours of tear fluid collection to minimize interference with baseline biomarker levels\n4. Willingness to comply with follow-up schedule and required visits\n5. No subject reported history of DED\n6. Schirmer ≥ 10 (without anesthesia)\n7. Best corrected visual acuity (BCVA) of 0.7 logMAR of better (logMAR \\\u003C0.7; Snellen equivalent score of 20\u002F100 or better) in each eye at the screening visit (Day 0).\n\nExclusion Criteria: (Non-DED) subjects not receiving Xiidra® (non-treatment arm)\n\n1. Active ocular infection within the last 30 days\n2. Any ocular surgical procedure within the last 6 months\n3. Unwilling to discontinue contact lens use for the duration of the study\n4. Pregnancy or lactation\n5. Any female of childbearing potential (FOCBP) who is unwilling to agree to: a) Have a urine pregnancy testing performed at Baseline (Day 0) b) Use at least 1 medically acceptable form of birth control for at least 14 days prior to the first dose of study drug, throughout the study duration, and for 1 month after the last dose of investigational drug. NOTE: FOCBP include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) NOTE: Acceptable forms of birth control include:\n\n   * Mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom)\n   * Hormonal contraceptive (oral, injectable, implantable, or transdermal)\n   * Intrauterine device, or\n   * Surgical sterilization of male partner at least 3 months prior to the first dose of investigational drug NOTE: For non-sexually active female subjects, abstinence may be regarded as an adequate method of birth control when this is in line with the preferred and usual lifestyle of the subject; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial.\n6. Any male who is unwilling to agree to use at least 1 medically acceptable form of birth control with female partner (FOCBP) who also is not using an acceptable form of birth control (as described above). NOTE: Acceptable forms of birth control include: True abstinence (when this is in line with the preferred and usual lifestyle of the subject), or Vasectomy at least 3 months prior to the first dose of study drug. Without a vasectomy, must use condoms with spermicidal foam, gel, film, cream, suppository at least 14 days prior to the first dose of investigational drug and throughout the study duration, and for 1 month after the last dose of the investigational drug.\n7. History of DED diagnosis\n8. Any ocular condition that, in the opinion of the investigator, could affect study parameters including, but not limited to, lid margin disorders (eg. Blepharitis, staphylococcal, demodex etc.)\n9. Any known history of immunodeficiency disorder, human immunodeficiency virus, hepatitis B or C, evidence of acute active hepatitis A (antihepatitis A virus immunoglobulin M), or organ or bone marrow transplant.\n10. Any known history of alcohol and\u002For drug abuse within 12 months prior to the screening visit that, in the opinion of the investigator, may have interfered with study compliance, outcome measures, safety parameters, and\u002For the general medical condition of the subject.\n11. Any subject that has punctal occlusion such as permanent\u002Fsemi-permanent punctal plugs, temporary plugs, punctal cauterization",{"count":128,"type":19},36,[106],"This is a single-center prospective open-label, clinical trial to explore proteomic expression of tear fluid biomarkers in patients with dry eye treated with Lifitegrast.",[23,132],"Dry Eye Syndrome (DES)",[134],"dry eye disease","NOT_YET_RECRUITING","2026-03-18",{"date":138,"type":31},"2026-03-24",{"date":140,"type":19},"2026-03",{"date":142,"type":19},"2026-11",{"name":144,"class":38},"Pittsburgh Research Institute",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":47,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":39},"100389720","treatment-of-ocular-discomfort-in-glaucoma-patients-using-multiple-topical-medications-100389720","NCT04354545","Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications","Inclusion Criteria:\n\n* Currently using one or more topical glaucoma antihypertensives\n* Self-described symptoms of ocular surface discomfort\n* Xiidra is being prescribed as part of the subject's standard care\n\nExclusion Criteria:\n\n* History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),\n* current use of topical cyclosporine\n* current use of topical steroids\n* incisional ocular surgery within 6 months",{"count":152,"type":19},75,"To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.",[155,23],"Glaucoma",[157,158,159],"glaucoma","xiidra™","ocular surface discomfort","2026-03-11",{"date":162,"type":31},"2026-03-13",{"date":164,"type":31},"2021-04-01",{"date":166,"type":19},"2026-12-01",{"name":168,"class":38},"University of California, Los Angeles",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":47,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":179,"conditions":180,"keywords":196,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":4},"100615866","wide-field-octa-in-ocular-diseases-100615866","NCT07298174","Wide Field OCTA in Ocular Diseases","Wide Field OCTA in Ocular Diseases: a Prospective Observational Study of the Clinical Impact of Wide Field OCTA in Ocular Disease.","WOOD-2025","Inclusion Criteria:\n\n* Age \\> 18 years\n* Both genders\n* Confirmed diagnosis of one of the above diseases\n* Age-related macular degeneration\n* Diabetic retinopathy\n* Myopia\n* Pachychoroid spectrum disease\n* Inherited retinal dystrophy\n* Uveitis\n* Dry eye\n* Visual acuity of at least 1\u002F20\n* Signed informed consent for the participation to the trial.\n\nExclusion Criteria:\n\n* Media opacities\n* Any other eye or systemic condition that may irreversibly impair the results of the study\n* Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment",{"count":178,"type":19},200,"The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function. Often, such diseases affect the noblest part of the retina, called macula. Many retinal diseases can be complicated by choroidal neovascularization which causes frequent bleeding and fluid leakage that accumulates in the subretinal and intraretinal spaces. Although the investigators know many details of each disease affecting the retina, very often the correct diagnostic framework can be complicated, given the presence of morphological elements common to the different pathologies. Similarly, predicting the effect of treatment and the patient's outcome is a constant challenge for the ophthalmologists. Most of the current research has been focused on the assessment of vascular alterations localized in the macula. However, growing evidence highlight the importance of peripheral vascular changes on the outcome of retinal diseases. These changes can be detected only be wide field OCT devices.\n\nOn the other hand, ocular inflammation and hyperemia represent major assessments in anterior segment disorders, such as dry eye disease. The current grading systems of ocular inflammation, redness and hyperemia are characterized by several limitations, thus making these evaluations still mainly confined to the subjective assessment performed by the ophthalmologist. However, the new generation OCT devices may include also an anterior segment module which can reconstruct anterior segment vessels, non-invasively, using the same technology described for retinal diseases.\n\nThe main goal of the study is to evaluate the diagnostic contribution of a new generation wide field OCTA device in ocular diseases, which has recently received CE marking. In particular, the investigators will evaluate this new generation device both in retinal and anterior segments diseases, testing for common points and differences with the standard of care non-invasive diagnostic devices. Secondary outcomes include the assessment of the correlation between the patient's visual function (visual acuity) and morphological changes (standard of care imaging assessment) highlighted by the wide field OCT device, with particular attention to microstructural differences between major ocular diseases and the possible development of non-invasive biomarkers, useful for the diagnosis and follow-up of such pathologies.",[181,182,183,184,185,186,187,188,189,190,23,191,192,193,194,195],"Age - Related Macular Degeneration (AMD)","Diabetic Macular Edema","Diabetic Retinopathy","Myopia","Inherited Retinal Disease","Stargardt Disease","Retinitis Pigmentosa (RP)","Best Disease","Geographic Atrophy","Macular Neovascularisation","Central Serous Choroidopathy","Pachychoroid Disease","Uveitis","Vitreoretinal Disease","Retinal Vein Occlusion",[197,198,199,200,201,86],"wide-field octa","multimodal retinal imaging","quantitative imaging","retinal disease","macular disease","2025-12-22",{"date":204,"type":31},"2025-12-30",{"date":206,"type":19},"2026-01",{"date":208,"type":19},"2028-05",{"name":210,"class":38},"IRCCS San Raffaele",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":51,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":39},"100615841","eyelid-closure-in-keratometry-100615841","NCT07297849","Eyelid Closure in Keratometry","The Effect of Eyelid Closure on the Quality Index of Keratometric Measurements: a Non-controlled Interventional Study","Inclusion Criteria:\n\n* Age 18 or older\n* Written informed consent\n* Keratometry quality index \"warning\"\n\nExclusion Criteria:\n\n* Severe corneal conditions that may compromise corneal integrity (such as corneal scarring, etc.)\n* Pregnancy (pregnancy test will be taken in women of reproductive age), nursing women\n* Ocular surgery in the study eye in the three months preceding the study\n* Inability of visual fixation (e.g. in patients with nystagmus)\n* Inability of eyelid closure (e.g. in patients with facial nerve paralysis)",{"count":219,"type":19},29,[53],"Cataract surgery is one of the most common performed surgeries in the world. While in the early beginnings of cataract surgery, visual rehabilitation was the main goal of the procedure, refractive outcome and subsequent relative spectacles independency is gaining increasing importance in patients' demands. Due to the improvements in measurement techniques and prediction formulas, the prediction of postoperative refraction is possible with high accuracy. However, there are still some sources of error that lead to deviations of predicted postoperative refraction. For instance, it was shown that tear film osmolarity, an established biomarker for dry eye disease (DED), plays an important role in preoperative precision of keratometry measurements. Keratometry, the measurement of corneal curvature, is an important part of preoperative biometry. Errors in preoperative keratometry measurements lead to nearly one-to-one deviations from the predicted refraction. Therefore, proper keratometry measurements are a key element in intraocular lens (IOL) power calculations. To counteract the issue of DED in preoperative biometry, the principle of using lubricating eye drops before ocular biometry has been investigated and it was shown that the use of ocular lubricants may lead to increased variability of keratometry measurements. From our clinical observations, another possible mechanism to improve keratometry is eyelid closure for some minutes. In contrast to the long-term use of ocular lubricants to stabilize the tear film, eyelid closure is an easy and fast intervention to possibly improve the precision of keratometry measurements. Additionally, a clinical trial investigating the usage of lubricating eye drops for two weeks found no improvement of variability of keratometry in DED patients.\n\nTherefore, this study aims to investigate the effect of eyelid closure on the quality index of keratometric measurements in patients with a warning for the quality of keratometric measurements. For this purpose, a single study day including 4 repeated measurements (2 without and 2 with lid closure for 3 minutes) using an ocular biometer (IOLMaster700) will be performed.",[57,23],"2025-12-16",{"date":202,"type":31},{"date":226,"type":31},"2024-11-07",{"date":228,"type":19},"2025-12-31",{"name":230,"class":38},"Vienna Institute for Research in Ocular Surgery",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":47,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":51,"phases":240,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":4},"100544934","phase-1-study-to-evaluating-pro-240-ophthalmic-solution-compared-to-optive-100544934","NCT06375343","Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®","Phase I Clinical Study to Evaluate the Safety and Tolerability of PRO-240 Ophthalmic Solution Compared to Optive® on the Ocular Surface of Ophthalmologically and Clinically Healthy Volunteers","Inclusion Criteria:\n\n* Having the ability to voluntarily give their signed informed consent.\n* Ophthalmologically and clinically healthy subjects.\n* Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.\n* Age ≥18 years.\n* Male or female gender.\n* Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO \\[Tubal Ligation\\]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the informed consent form \\[ICF\\]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.\n* Best corrected visual acuity (BCVA) of 20\u002F30 or better in both eyes.\n* Corneal staining ≤ grade I on the Oxford Scale.\n* Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.\n\nExclusion Criteria:\n\n* History of hypersensitivity to any of the components of the drugs under investigation.\n* Use of ophthalmic medications from any pharmacological group.\n* Use of medications by any other route of administration.\n* Use of non-steroidal anti-inflammatory drugs, steroid anti-inflammatory drugs, or antibiotics by any route of administration in the last 30 days.\n* History of eye surgery in the last 6 months.\n* Use of contact lenses for a period less than two weeks prior to the start of the study, and during the intervention period of this study.\n* In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.\n* Having participated in any clinical research study 30 days prior to inclusion in this study.\n* Having previously participated in this same study.\n* History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension.\n* Diagnosis of glaucoma or ocular hypertension.\n* Known diagnosis of liver or heart disease.\n* Presenting active inflammatory or infectious disease at the time of entry into the study.\n* Presenting unresolved lesions or traumas at the time of entry into the study.\n* Having been subjected to non-ophthalmological surgical procedures in the last 3 months.\n* Being or having an immediate family member (e.g., spouse, parent\u002Flegal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study.\n* Active smoking (specified as the consumption of cigarettes regardless of the amount and frequency, 4 weeks prior to study inclusion and during the intervention period of this study).\n* Active alcoholism (specified as the consumption of alcoholic beverages, regardless of the amount and frequency, 72 hours prior to study inclusion and during the intervention period of this study).\n\nElimination Criteria:\n\n* Withdrawal of their consent to participate in the study (informed consent form).\n* Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and\u002For the sponsor, could affect the patient's fitness to safely continue with the study procedures.\n* Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).\n* Non-tolerability or hypersensitivity to any of the drugs under investigation.\n* Adherence \\\u003C 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.",{"count":239,"type":19},32,[241],"PHASE1","This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.",[244,245,23],"Dry Eye Disease","Dry Eye Sensation","2025-03-18",{"date":248,"type":31},"2025-03-19",{"date":250,"type":19},"2026-01-30",{"date":252,"type":19},"2027-01-30",{"name":254,"class":69},"Laboratorios Sophia S.A de C.V.",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":15,"minAge":262,"maxAge":48,"enrollmentInfo":263,"targetDuration":4,"studyType":51,"phases":264,"briefSummary":265,"conditions":266,"keywords":272,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":4},"100577070","phase-1-efficacy-and-safety-of-oral-probiotics-on-ocular-symptoms-and-gut-microbiome-of-children-with-vernal-keratoconjunctivitis-100577070","NCT06793514","Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis","Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis: a Double-blind Clinical Trial Study","Inclusion Criteria:1- Patients whose diagnosis of vernal keratoconjunctivitis is confirmed based on clinical criteria. 2-Patients with an age range of 4 to 18 years. 3-Patients who have not received drug treatment for vernal keratoconjunctivitis disease recently.\n\n\\-\n\nExclusion Criteria:1-Having other eye diseases (except refractive error) 2-Change in the diagnosis of the disease during the study 3-Antibiotics, anti-inflammatory drugs, immunosuppressive drugs 4-History of known gastrointestinal diseases (such as IBD, Celiac,...) 5- History of digestive problems in the last two weeks 6- Lack of consent to participate in the study 7- Having an eye infection in the last one month 8- People who were athletes or involved in intense physical activity 9- Smoking, alcohol and drugs. 10- Using drugs that affect appetite, bowel movements, and nutrient absorption 11- Using prebiotics, probiotics or synbiotics in the last 3 months 12- People who have been on a diet to lose or gain weight in the last 3 months 13- People who have undergone gastrointestinal surgery. 14- Changing the patient's diagnosis in the course of treatment 15- Failure to follow up the patient at the specified times for the visit and assessment of the patient's bed 16- Taking fat-reducing drugs 17-Oral hypoglycemic drugs, insulin, antihypertensive drugs-18- Diuretics, laxatives, antacids 19-Food supplements in the last 3 months.\n\n\\-","4 Years",{"count":239,"type":19},[241],"The primary goal of this study is to determine the effects of oral probiotics on the severity of ocular symptoms and the alterations of the gut microbiome of children (4-18 years old) with vernal keratoconjunctivitis. The current study will also assess the safety of oral probiotics among children with vernal keratoconjunctivitis. The main questions it aims to answer: 1- Does treatment with oral probiotics improve the severity of ocular symptoms in children with vernal keratoconjunctivitis? 2- Does treatment with oral probiotics alter the gut microbiome of children with vernal keratoconjunctivitis? Researchers will compare the ocular symptoms and gut microbiome between two groups receiving oral probiotics and placebo among children with vernal keratoconjunctivitis.\n\nParticipants The participants will receive the oral probiotics and placebo ever day for one month.\n\nRecord their regimen and keep a diary of their symptoms.",[267,23,268,269,270,271],"Probiotic","Ocular Diseases","Ocular Dryness","Gut Microbiome Dysbiosis","Gut -microbiota",[267,273,274,275],"Vernal keratoconjunctivitis","Clinical trial","gut microbiome","2025-01-21",{"date":278,"type":31},"2025-01-27",{"date":280,"type":19},"2025-02-01",{"date":282,"type":19},"2025-06-01",{"name":284,"class":38},"Mohsen Pourazizi",{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":293,"conditions":294,"keywords":295,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":39},"100571019","analysis-of-videodermatoscopic-parameters-of-ocular-periocular-conjunctival-and-palpebral-neoformations-100571019","NCT06714799","Analysis of Videodermatoscopic Parameters of Ocular, Periocular, Conjunctival and Palpebral Neoformations","Inclusion Criteria:\n\n* patients who had been diagnosed with one of the following conditions in the ocular and periocular region: common melanocytic nevus, melanosis, seborrheic keratosis, viral wart, angioma and angiokeratoma, apocrine hydrocystoma, xanthelasma, steatocystoma, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, melanoma.\n\nExclusion Criteria:\n\n* Patients who presented with one of the following conditions were excluded from the study: concomitant inflammatory processes, including blepharitis, chalazion, pterygium, pinguecula), coexistence of multiple, periocular or ocular lesions, diagnosis of syndromic diseases related to a major risk for cutaneous neoformations.",{"count":292,"type":19},300,"ANALYSIS OF VIDEODERMATOSCOPIC PARAMETERS OF OCULAR, PERIOCULAR, CONJUNCTIVAL AND PALPEBRAL NEOFORMATIONS",[23],[296,297],"videodermatoscopia","occhi","2024-12-03",{"date":300,"type":31},"2024-12-05",{"date":302,"type":31},"2021-06-15",{"date":304,"type":19},"2030-12-15",{"name":306,"class":38},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":51,"phases":316,"briefSummary":317,"conditions":318,"keywords":322,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":39},"100564070","phase-1-efficacy-and-safety-of-topical-cyclosporine-005-and-lifitgrast-on-the-ocular-surface-symptom-after-photorefractive-keratectomy-in-feiz-hospital-isfahan-2024-100564070","NCT06624384","Efficacy and Safety of Topical Cyclosporine 0.05% and Lifitgrast on the Ocular Surface Symptom After Photorefractive Keratectomy in Feiz Hospital, Isfahan, 2024","Efficacy and Safety of Topical Cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) on the Ocular Surface Symptom After Photorefractive Keratectomy (PRK) in Feiz Hospital, Isfahan, 2024","Inclusion Criteria:\n\nAge above 18 years Myopia and myopic astigmatism The stability of the patients refraction over the past year Not using contact lenses at least 3 weeks before the operation Absence of history of KCN and any type of corneal ectasia in the patient himself or his first degree family No history of previous eye surgery and eye trauma Absence of active eye diseases, corneal dystrophy, retinal diseases, glaucoma, dry eyes of any degree.\n\nAbsence of systemic diseases that can potentially disrupt wound healing, including diabetes, vascular collagen diseases, and pregnancy.\n\nNot taking inhaled or systemic steroids actively or within 3 months before the procedure Absence of anisometropia Not using any systemic and topical analgesia during the last week\n\nExclusion Criteria:\n\nThe patients lack of consent to continue the study Failure to visit the patient for follow-up The occurrence of any complications during the patients surgery",{"count":315,"type":19},150,[241],"The goal of this clinical trial is to compare the administration of 2 drugs, cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) before PRK, in reducing the ocular surface symptom of patients after PRK. The main questions it aims to answer are:\n\n1- Does the use of cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) before photorefractive keratectomy surgery (PRK) reduce ocular surface symptom such as eye pain, redness, and inflammation in conjunctivitis in patients? Researchers will compare cyclosporine 0.05% (Restasis) and Lifitgrast (Xiidra) to a placebo (Artelac artificial tears) to see if cyclosporine 0.05% and Lifitgrast works to reduce ocular surface symptom.\n\nParticipants will:\n\nTake drug cyclosporine 0.05% and Lifitgrast or a Artelac 30 minutes before surgery Visit the clinic 6 hours, one day, three days and one week after photorefractive keratectomy (PRK) for checkups and tests",[319,23,320,321],"Ocular Surface Symptom","Eye Pain","Eye Inflammation",[323],"PRK- ocular surface symptom - cyclosporine 0.05% - Lifitgrast (Xiidra)","2024-09-30",{"date":326,"type":31},"2024-10-03",{"date":328,"type":19},"2024-10-30",{"date":330,"type":19},"2024-12-30",{"name":284,"class":38},{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":39},"100558764","clinical-application-research-of-scleral-lenses-in-ocular-surface-diseases-100558764","NCT06555367","Clinical Application Research of Scleral Lenses in Ocular Surface Diseases","Inclusion Criteria:\n\n* Patients with irregular corneal astigmatism, including those with post-keratoconus cross-linking surgery, post-keratoplasty, and corneal irregularities caused by trauma; Volunteers who are willing to participate in this trial, have signed the informed consent form, and are willing to cooperate with the treatment and follow-up; Individuals aged 18 years or older (including 18 years old), with no gender restrictions; Cases collected from January 2023 to August 2024.\n\nExclusion Criteria:\n\n* Unable or unwilling to sign the consent form, or unable to follow the study procedures; Nursing or pregnant women; Individuals with acute ocular inflammation or infection; Corneal endothelium: Cell Density (CD) \\\u003C1000\u002Fmm²; Individuals required to wear lenses overnight; Poor compliance; Those who do not meet the hygiene requirements for lens wear; Individuals whom the investigator deems have other reasons making them unsuitable for the trial.",{"count":339,"type":19},20,"To evaluate the therapeutic efficacy of scleral lenses in patients with irregular corneal astigmatism stemming from ocular surface diseases (OSD), focusing on visual acuity improvement, comfort, and overall satisfaction. This prospective clinical study enrolled patients diagnosed with OSD-related irregular corneal astigmatism. Participants underwent comprehensive ophthalmic evaluation, including corneal topography, visual acuity assessment, and tear film analysis. Qualified subjects were fitted with scleral lenses and followed up at intervals of one week, one month, and three months post-fitting. The primary outcomes measured were uncorrected and corrected visual acuity, comfort levels assessed via a standardized questionnaire, and fitting success rates. Data were analyzed using appropriate statistical methods to compare pre- and post-intervention values.",[23],"2024-08-13",{"date":344,"type":31},"2024-08-15",{"date":346,"type":19},"2024-08-08",{"date":348,"type":19},"2026-08-31",{"name":350,"class":38},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":47,"sex":15,"minAge":358,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":51,"phases":362,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":39},"100548948","investigator-initiated-clinical-trial-to-observe-conjunctival-goblet-cell-using-an-anterior-segment-imaging-device-100548948","NCT06427629","Investigator-initiated Clinical Trial to Observe Conjunctival Goblet Cell Using an Anterior Segment Imaging Device","Investigator-initiated Exploratory Clinical Trial to Observe Conjunctival Goblet Cell Density Using an Anterior Segment Imaging Device in Patients With Ocular Surface Disease (ODS) and Patients Scheduled for Ocular Surgery Without OSD","Inclusion Criteria:\n\n* Adult patients aged 19 years or older.\n* Patients who are currently using or scheduled to use 0.5% moxifloxacin eye drops for ophthalmic surgery (control group) or for ocular surface diseases (patient group: dry eye, Sjogren's syndrome, Stevens-Johnson syndrome, graft versus host disease).\n* Patients who have agreed to understand and comply with the clinical trial protocol's plans for medical examinations and follow-up observations.\n\nExclusion Criteria:\n\n* Pregnant or planning to become pregnant, and lactating women.\n* Patients with intellectual disabilities and other psychiatric disorders who, at the discretion of the investigator, are deemed ineligible for participation in the clinical trial.\n* Patients with hypersensitivity reactions to 0.5% moxifloxacin eye drops, or patients for whom administration is contraindicated.\n* Patients for whom participation in the study is deemed impractical based on the judgment of other medical staff and neutral observers (excluding specified selection\u002Fexclusion criteria, based on medical reasons, ethical considerations, low compliance, and understanding of the study).","19 Years","85 Years",{"count":361,"type":19},148,[53],"Conjunctival goblet cells secrete mucin, vital for tear film stability. Dysfunction can cause tear film issues and lead to diseases like dry eye. Imaging these cells is crucial for diagnosis and treatment. 0.5% moxifloxacin eye drops, an FDA-approved antibiotic, are used to treat bacterial eye infections and prevent infections before surgeries. The investigators developed a non-invasive imaging method for goblet cells, validated in animals, and now plan to test it in humans for diagnosing and treating ocular surface diseases.",[23],"2024-06-18",{"date":367,"type":31},"2024-06-20",{"date":369,"type":31},"2024-06-12",{"date":371,"type":19},"2026-06",{"name":373,"class":38},"Seoul National University Hospital",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":15,"minAge":381,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":39},"100539057","the-pattern-of-dry-eye-disease-after-cataract-surgery-100539057","NCT06298890","The Pattern of Dry Eye Disease After Cataract Surgery","Ocular Surface and Corneal Morphological Changes After the Cataract Surgery and Associations With Inflammatory Biomarkers","Inclusion Criteria:\n\n* Cataract patients from 50 to 90 years old who underwent uncomplicated phacoemulsification performed by one (and same) experienced surgeon.\n* Patients with no underlying ocular surface diseases (keratitis, keratoconjunctivitis and others).\n* Patients who previously did not undergo any ophthalmic surgery.\n\nExclusion Criteria:\n\n* Patient expressed his wish to not participate in the study or discontinue it when already enrolled.\n* Severe dry eye disease diagnosed with OSDI\u002FDEQ-5 and at least one of the following tests: TBUT less than 10 seconds, tear osmolarity higher than 308 mOsm\u002Fl or positive corneal staining.\n* Glaucoma.\n* Diabetes mellitus.\n* Systemic connective tissue disease, autoimmune disease.\n* Neurologic conditions including stroke, Bell's palsy, Parkinson's, trigeminal nerve dysfunction.\n* Patients who underwent refractive surgery (LASIK or PRK).\n* Contact lens users.\n* One or more of the following concomitant medications: psychiatric medicines, antihistamines and\u002For hormonal replacement.\n* Patients who are already regularly using topical drops or ointments.","50 Years","90 Years",{"count":384,"type":19},100,"This study is designed to explore dry eye disease (DED) pattern: ocular surface, corneal morphological changes, patients' subjective assessment of DED and their correlations with ocular surface inflammation, pain biomarkers after cataract surgery according to ocular surface lubrication with artificial tears during long-term follow-up.",[244,387,23],"Cataract","2024-03-01",{"date":390,"type":31},"2024-03-07",{"date":392,"type":19},"2024-03",{"date":394,"type":19},"2027-09",{"name":396,"class":38},"Lithuanian University of Health Sciences"]